Tyloxapol

Tyloxapol
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R05CA01 (WHO) ;
Identifiers
	IUPAC name formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol;
CAS Number	25301-02-4 ;
PubChem CID	71388;
DrugBank	DB06439 ;
ChemSpider	None;
UNII	Y27PUL9H56;
KEGG	D03261 ;
ChEBI	CHEBI:141517;
ChEMBL	ChEMBL1201548 ;
CompTox Dashboard (EPA)	DTXSID30179950 ;
ECHA InfoCard	100.209.660
Chemical and physical data
Formula	(C15H21O(C2H4O)m)n
Molar mass	variable
	(what is this?) (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]

Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are Exosurf and Alevaire.

References

Sehgal SS, Ewing CK, Richards T, Taeusch HW (January 1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.
Rubin BK, Ramirez O, King M (April 1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–5. doi:10.1378/chest.101.4.1080. PMID 1555424.
"Tyloxapol definition". Drugs.com.
Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN (October 2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and Molecular Pathology. 73 (2): 135–8. doi:10.1006/exmp.2002.2449. PMID 12231215.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Sehgal SS, Ewing CK, Richards T, Taeusch HW (January 1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study". Journal of the National Medical Association. 86 (1): 46–52. PMC 2607653. PMID 8151722.

[2] Rubin BK, Ramirez O, King M (April 1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest. 101 (4): 1080–5. doi:10.1378/chest.101.4.1080. PMID 1555424.

[3] "Tyloxapol definition". Drugs.com.

[4] Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN (October 2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and Molecular Pathology. 73 (2): 135–8. doi:10.1006/exmp.2002.2449. PMID 12231215.